In , Fredun Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +45.5% relative strength. Fundamentals: Weak. On a 9-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: Gross Margin of new brands: 50-70%
Impact: Sudden increase in profits
“Margin growth, you will see a sudden increase after a few quarters once the cost efficiencies of the new-age brands start kicking in because they are intrinsically higher gross margin products, 50%, 60%, 70%”
What: State expansion: 4-5 new states
Impact: 60% India coverage
“I'm talking about the coming year because we are adding another 4 to 5 states, and that will kind of complete almost 60% of India.”
What: Operational leverage timeline: 9 months
Impact: Not Given
“Maharashtra will start getting operationally leveraged, say, within 9 months... in the next 5 to 6 quarters, you will see a good set of numbers”
What: Q3 Revenue growth of 57% YoY
“Currently, the way we are anticipating that the new brands which we have launched in the last 2, 3 years are suddenly taking a lot of traction.”
Earnings deceleration risks from management commentary
Trigger: The analyst specifically questioned the outlook on key raw material costs.
Management view: Management believes that while they cannot sustain the same percentage growth as they get bigger, operational efficiencies will offset costs.
Monitor: commodity
Trigger: Licensing requirements force the company to use 37 partner facilities for specific products.
Management view: The company uses contract manufacturing to maintain asset-light growth for these specific lines.
Monitor: regulatory
Key quotes from recent conference calls
“And also, you had mentioned in the last call of a INR90 crores PAT guidance for FY'29. So is that intact or we can expect much more than that? [Previous FY29 PAT Guidance guidance]”
“We consider next 5 to 7 years, it can, 5 to 7 years, the Wagr revenue itself can be a few million dollars a month. [Initiative: Wagr Platform Launch]”
“And what is your outlook on key raw material costs over the next 2 to 3 years? ... On a larger number, it is not possible to sustain a number. [Risk (commodity): MEDIUM]”
“where we ourselves will manufacture products, which we cannot manufacture in our own facilities due to licensing constraints, due to other MOQs and stuff like that. [Risk (regulatory): LOW]”
Headline numbers from the latest earnings call
Revenue
INR 160.92 crores
Why: Growth was driven by new brands launched in the last 2-3 years gaining traction and strong performance in the new-age business verticals.
Revenue growth significantly outpaced the legacy business growth rate due to new-age vertical contributions.
EBITDA
INR 26.34 crores
Why: Margin expansion was driven by operational efficiencies and a shift toward high-margin businesses like dermaceutics and pet care.
EBITDA growth nearly doubled year-on-year, reflecting significant operating leverage as new verticals scale.
PAT
INR 10.48 crores
Why: Profitability improved due to the higher contribution of high-margin products and improved net profit margins reaching 7%.
PAT growth remains high, though management maintains a conservative stance on sustainable long-term PAT margins.
Other Highlights
• 9-month total income reached INR 426 crores, marking 48% year-on-year growth.
• EBITDA margin for the 9-month period expanded by 237 basis points to 15%.
• Net profit for the 9-month period increased 96% to INR 26.98 crores.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Registrations in Pipeline
1,300 to 1,400
Why: The pipeline is built to support the 12% to 18% growth target for the vintage business.
Export Revenue (Direct)
INR 118-120 crores
Why: Base figure from the previous year used to project 15-20% growth in the current 9-month period.
New-Age Business Revenue Share Target
51%
Why: Strategic shift to focus on high-margin verticals like pet care and nutraceuticals.
Pet Care Revenue (Projected)
INR 42 crores
Why: Driven by the Freossi brand and new launches like Snacky Jain.
Nutritional Business Revenue (Projected)
INR 26 crores
Why: Growth in nutraceuticals supported by double-blinded clinical trials.
Gx Business Revenue (Projected)
INR 60 crores
Why: Steady growth in the branded generics segment.
F&D Team Size
40 people
Why: Management highlights this as a strength for a company of their size to drive innovation.
Outsourced Product Mix
5% to 7%
Why: Expected to increase to 15-20% as the company adopts an asset-light model for new categories.
Forward-looking targets from management for FY26-end
OPM Guidance
6%
Capex Plan
₹12 Cr
INR 600 crores
Management targets a conservative PAT margin.
INR 9-12 crores
Investment in Wagr platform and website development.
Guidance Changes
FY29 PAT Guidance: INR 90 crores → INR 90 crores
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| OPM | 16.0% | — | Insufficient Data |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Fredun Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Fredun Pharmaceuticals Ltd's profit is declining with an insufficient_data trend.
Fredun Pharmaceuticals Ltd's revenue growth trend is insufficient_data.
Fredun Pharmaceuticals Ltd's operating margin is insufficient_data.
Fredun Pharmaceuticals Ltd's earnings growth is insufficient_data with positive momentum on a sequential basis.
Fredun Pharmaceuticals Ltd appears significantly overvalued based on our fair value analysis.
Fredun Pharmaceuticals Ltd's current PE ratio is 37.6x.
Fredun Pharmaceuticals Ltd's current PE is 37.6x.
Fredun Pharmaceuticals Ltd's price-to-book ratio is 7.6x.
Fredun Pharmaceuticals Ltd is rated Weak with a fundamental score of 27.69/100. This score is calculated from objective financial metrics
Fredun Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Fredun Pharmaceuticals Ltd's operating cash flow is negative (FY2025).
Fredun Pharmaceuticals Ltd's current dividend yield is 0.03%.
Fredun Pharmaceuticals Ltd's shareholding pattern (Apr 2026)
Fredun Pharmaceuticals Ltd's promoter holding has increased recently.
Fredun Pharmaceuticals Ltd has been outperforming Nifty 500 for 9 consecutive weeks, indicating consistent outperformance.
Fredun Pharmaceuticals Ltd is an established outperformer with 9 weeks of consecutive Nifty 500 outperformance.
Fredun Pharmaceuticals Ltd has 4 key growth catalysts identified from recent earnings analysis
Fredun Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26, Fredun Pharmaceuticals Ltd's management highlighted
Fredun Pharmaceuticals Ltd's management has provided the following forward guidance for FY26-end
Fredun Pharmaceuticals Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Fredun Pharmaceuticals Ltd may be worth studying
Fredun Pharmaceuticals Ltd investment thesis summary:
Fredun Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
